Zentalis Pharmaceuticals Llc (ZNTL) - Total Assets
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) holds total assets worth $288.97 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ZNTL book value for net asset value and shareholders' equity analysis.
Zentalis Pharmaceuticals Llc - Total Assets Trend (2018–2025)
This chart illustrates how Zentalis Pharmaceuticals Llc's total assets have evolved over time, based on quarterly financial data.
Zentalis Pharmaceuticals Llc - Asset Composition Analysis
Current Asset Composition (December 2025)
Zentalis Pharmaceuticals Llc's total assets of $288.97 Million consist of 87.6% current assets and 12.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.5% |
| Accounts Receivable | $1.93 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Zentalis Pharmaceuticals Llc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ZNTL market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zentalis Pharmaceuticals Llc's current assets represent 87.6% of total assets in 2025, an increase from 65.1% in 2018.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2025, down from 61.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 30.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Zentalis Pharmaceuticals Llc Competitors by Total Assets
Key competitors of Zentalis Pharmaceuticals Llc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Zentalis Pharmaceuticals Llc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.93 | 7.32 | 9.34 |
| Quick Ratio | 6.93 | 7.32 | 9.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $216.63 Million | $333.34 Million | $273.56 Million |
Zentalis Pharmaceuticals Llc - Advanced Valuation Insights
This section examines the relationship between Zentalis Pharmaceuticals Llc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -32.9% |
| Total Assets | $288.97 Million |
| Market Capitalization | $195.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zentalis Pharmaceuticals Llc's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Zentalis Pharmaceuticals Llc's assets decreased by 32.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zentalis Pharmaceuticals Llc (2018–2025)
The table below shows the annual total assets of Zentalis Pharmaceuticals Llc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $288.97 Million | -32.85% |
| 2024-12-31 | $430.34 Million | -23.43% |
| 2023-12-31 | $562.03 Million | +1.55% |
| 2022-12-31 | $553.46 Million | +17.25% |
| 2021-12-31 | $472.02 Million | +29.13% |
| 2020-12-31 | $365.56 Million | +314.31% |
| 2019-12-31 | $88.23 Million | +115.21% |
| 2018-12-31 | $41.00 Million | -- |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more